● Recruiting

A First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With TTX-381 for the Ocular Manifestations Associated With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease

Condition: Neuronal Ceroid Lipofuscinosis Type 2 · Sponsor: Tern Therapeutics, LLC

PhasePhase 1/Phase 2

Planned participants16

Who can joinAll sexes, 12 Months to 84 Months

Healthy volunteersNo

About this study

This is a first-in-human, open-label, single ascending dose study of TTX-381 for the treatment of ocular manifestations of CLN2 (Batten disease).

This description comes directly from the study's public registry record.

Talk to the study team

Tern Therapeutics Patient Advocacy · 202-644-8488 · patientadvocacy@terntx.com

Always discuss trial participation with your own doctor first.

Locations (2)

University Medical Center Hamburg-Eppendorf (UKE)- Childrens Hospital	Hamburg, Germany	Recruiting
Greater Ormond Street Hospital	London, United Kingdom	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05791864